RA Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16M Hold
4,178,823
– – 0.16% 64
2026
Q2
$23.7M Hold
4,178,823
– – 0.21% 59
2026
Q1
$38.2M Hold
4,178,823
– – 0.41% 41
2025
Q4
$66.9M Hold
4,178,823
– – 0.69% 29
2025
Q3
$195M Hold
4,178,823
– – 2.4% 12
2025
Q2
$122M Hold
4,178,823
– – 2.06% 13
2025
Q1
$107M Hold
4,178,823
– – 1.79% 13
2024
Q4
$121M Hold
4,178,823
– – 1.61% 16
2024
Q3
$99.2M Hold
4,178,823
– – 1.14% 26
2024
Q2
$72.3M Hold
4,178,823
– – 0.96% 30
2024
Q1
$93.3M Buy
+4,178,823
New +$86.9M 1.19% 25
2022
Q2
– Sell
-385,481
Closed -$13.8M – 101
2022
Q1
$13.8M Hold
385,481
– – 0.3% 68
2021
Q4
$33.5M Hold
385,481
– – 0.59% 50
2021
Q3
$44.2M Hold
385,481
– – 0.61% 42
2021
Q2
$82.9M Buy
+385,481
New +$67.1M 1.33% 23

Other funds holding LENZ

RA Capital Management's LENZ Position: Q3 2026 in Review

RA Capital Management held its LENZ Therapeutics (LENZ) position steady in Q3 2026 at 4,178,823 shares worth $16M. The position accounts for 0.16% of the portfolio, ranked #64.

RA Capital Management first reported a position in LENZ in Q2 2021 and has held it in 15 quarters since. The position peaked at $195M in Q3 2025. 138 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

  • RA Capital Management held 4,178,823 shares of LENZ Therapeutics worth $16M as of Q3 2026.
  • RA Capital Management left its LENZ Therapeutics share count unchanged in Q3 2026.
  • LENZ Therapeutics made up 0.16% of RA Capital Management's portfolio in Q3 2026, its #64 holding.
  • RA Capital Management first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • RA Capital Management's LENZ Therapeutics position peaked at $195M in Q3 2025.
  • 138 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on RA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.